GYRE · Gyre Therapeutics, Inc. · Metrics
$7.09
+0.56 (+8.58%)
At close · Oct 28
Return incl. dividend (before tax)
Market Cap
$728.16M
Shares
111.51M
Volume · Oct 28
125.15K
Avg daily vol (3M)
120.21K
GYRE metrics
85 of 122 screener metrics currently available.
Market overview
2 metricsShare price
$7.09
Market cap
$728.16M
Price action
20 metricsPrice change (1W)
+5.8%
Price change (30D)
-12.8%
Price change (3M)
+9.0%
Price change (6M)
-14.9%
Price change (YTD)
-7.5%
Price change (1Y)
-18.6%
Trailing year
Price change (5Y)
—
52-week high
$8.76
52-week low
$5.56
Change from 52-week high
-25.5%
Change from 52-week low
+17.4%
Annualized volatility
55.5%
Annualized volatility (3M)
49.2%
Beta
1.4
RSI (14D)
49.6
Price vs SMA 50
-3.9%
Price vs SMA 200
-6.9%
Avg volume (3M)
118,777
Relative volume
1.1
Average dollar volume
$822,460
Company
3 metricsSector
Healthcare
Industry
Biotechnology
Shares outstanding
111.51M
Valuation
12 metricsP / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
5.3×
reciprocal yield 18.8%
EV / EBITDA
—
EV / EBIT
—
P / sales
5.8×
reciprocal yield 17.2%
P / book
6.3
reciprocal yield 15.9%
FCF yield
-0.9%
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-3.8%
Historical valuation
8 metricsP / E historical average (3Y)
450.5×
reciprocal yield 0.2%
P / E historical average (5Y)
450.5×
reciprocal yield 0.2%
EV / revenue historical average (3Y)
6.4×
reciprocal yield 15.7%
EV / revenue historical average (5Y)
2.4×
reciprocal yield 41.0%
EV / EBIT historical average (3Y)
65.6×
reciprocal yield 1.5%
EV / EBIT historical average (5Y)
52.4×
reciprocal yield 1.9%
EV / EBITDA historical average (3Y)
110.9×
reciprocal yield 0.9%
EV / EBITDA historical average (5Y)
88.6×
reciprocal yield 1.1%
Dividends & buybacks
7 metricsDividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
1.9%
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—
Earnings calendar
2 metricsNext earnings
—
Last earnings
2021-11-12
Profitability
9 metricsGross margin
94.2%
Operating margin
-10.5%
Trailing 12 months
Net margin
-22.1%
Gross profit (TTM)
$109.61M
Operating profit (TTM)
−$12.26M
Net income (TTM)
−$25.67M
Trailing 12 months
Diluted EPS (TTM)
$-0.17
FCF margin
-5.2%
Effective tax rate
—
Growth
11 metricsRevenue growth YoY
-2.1%
Year over year
Net income growth YoY
-44.8%
Revenue (TTM)
$116.42M
Trailing 12 months
EPS growth YoY
-60.0%
Shares change YoY
+12.8%
Year over year · more shares
Revenue CAGR (3Y)
+4.5%
Revenue CAGR (5Y)
+41.0%
EPS CAGR (3Y)
-12.6%
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—
Quality
14 metricsReturn on equity
-23.8%
Return on assets
-12.9%
Debt / equity
0.0
Current ratio
4.3
EBITDA (TTM)
−$9.17M
Free cash flow (TTM)
−$6.11M
Quick ratio
3.9
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$57.34M
Latest balance sheet
Cash & equivalents
$43.29M
Total assets
$199.25M
Total debt
$0
Cash flow & spend
7 metricsOperating cash flow (TTM)
−$4.93M
Capital expenditures (TTM)
$1.17M
R&D (TTM)
$17.34M
SG&A (TTM)
—
Stock compensation (TTM)
$9.87M
R&D / revenue
—
Stock compensation / revenue
8.5%
Ownership (13F)
9 metrics13F filers
60
13F filer change QoQ
+4
Institutional ownership
7.8%
Conviction holders (share of 13F filers)
1.7%
Crowding (high-turnover and private-fund holders)
1.1%
Private-fund adviser ownership
1.1%
Active holders' share change QoQ
+807.8%
Holder tenure
3.6
Price vs estimated holder cost
-6.6%
Ownership (registered funds)
1 metricsIndex-fund ownership
2.0%
Short interest
3 metricsShort interest
1.7%
Latest settlement · 16.3 days to cover
Days to cover
16.3d
Short-squeeze score
69 / 100
Insider activity
2 metricsNet insider buying (90D)
—
Insider-sentiment score
—
Risk flags
1 metricsGoing concern
—